EEG clues may reveal who benefits from seizure drug

NCT ID NCT07555171

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study looks at whether specific brain wave patterns on an EEG can predict how well the drug fenfluramine works for people with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy. Researchers will follow 20 children and adults aged 2 to 35 who are already taking fenfluramine. The goal is to find EEG markers that show if the drug is helping, giving doctors a better way to tailor treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fenfluramine
What this could lead to: If successful, this could help doctors predict which LGS patients will benefit most from fenfluramine, personalizing treatment.
What could go wrong: This is a small, early-stage observational study with only 20 participants, so results may not apply broadly. It focuses on markers, not a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME (LGS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lennox-Gastaut syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LENNOX GASTAUT SYNDROME (LGS)

Contacts and locations

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.